
“Unlocking the Potential: A Comprehensive Look at Biohaven’s NDA Review for Troriluzole and its Impact Beyond 2025”
Biohaven’s NDA for Troriluzole in spinocerebellar ataxia Accepted by FDA with Priority Review Exciting news in the world of pharmaceuticals as Biohaven’s New Drug Application (NDA) for Troriluzole in the treatment of spinocerebellar ataxia has been accepted by the FDA with Priority Review status. This development could potentially lead to approval as early as Q3…